Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
(RTTNews) - Quest Diagnostics (DGX), a diagnostic information services provider, announced Wednesday that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
The enzyme-linked immunosorbent in vitro diagnostic assay is for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum. The test is intended to be used in conjunction with other available clinical information.
The test helps identify patients eligible for treatment with Sarepta Therapeutics, Inc.'s (SRPT) ELEVIDYS (delandistrogene moxeparvovec-rokl), gene therapy for certain individuals with Duchenne muscular dystrophy.
In addition, Quest and Sarepta announced an expanded collaboration under which Quest will develop one or more companion or complementary diagnostics in connection with Sarepta's portfolio of investigational and on-market gene therapies.
The breakthrough Device Designation is an FDA process designed to expedite the development and review of certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
Quest Diagnostics Boosts FY23 Adj. EPS, Revenue Outlook - Update
